Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions (AlloRé)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Patricia MARINO
- Phone Number: +33 04.91.22.35.02
- Email: patricia.marino@inserm.fr
Study Locations
-
-
-
Saint-Pierre, France, 97448
- CHU de la Réunion
-
Contact:
- Lucie AUZANNEAU
- Email: lucie.auzanneau@chu-reunion.fr
-
Principal Investigator:
- Patricia ZUNIC, PH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome
- candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;
- Residing in Reunion Island
- Age >18 year old;
- who accept or not allogeneic hematopoietic
- Able to complete a questionnaire
Exclusion Criteria:
- Opposition to participation and collection of their data
- Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)
|
|
|
patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quality of life Functional Assessment of Cancer Therapy - Bone Marrow Transplantation questionnaire. (FACT-BMT questionnaire)
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
satisfaction with decision questionnaire
Time Frame: 24 months
|
24 months
|
|
|
decision regret scale
Time Frame: 24 months
|
24 months
|
|
|
fear of recurrence questionnaire
Time Frame: 24 months
|
24 months
|
|
|
preferences of patients questionnaire
Time Frame: 24 months
|
24 months
|
|
|
cost of treatment
Time Frame: 24 months
|
impact on patients and caregivers; impact on society
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2020/CHU/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.